Chronic Kidney Disease Competitive Landscape Report 2023: Comprehensive Insights About 75+ Companies and 95+ Drugs

The “Chronic Kidney Disease – Competitive landscape, 2023” report has been added to’s offering.

This report provides comprehensive insights about 75+ companies and 95+ drugs in Chronic Kidney Disease Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In March 2023, POXEL SA, announced the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. For the first time, POXEL SA showed beneficial effects of a direct and selective AMPK activator in preclinical ADPKD models from three species mouse, human, and dog. These results confirm the potential utility of AMPK activation for this disease and support the development of PXL770 in a Phase 2 clinical program for ADPKD.

In February 2023, AstraZeneca announced the successful completion of the acquisition of CinCor Pharma, Inc. The acquisition bolsters AstraZeneca’s cardiorenal pipeline by adding baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension, to its cardiorenal portfolio.

In January 2023, The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company announced.

In November 2022, The Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, which designed, conducted and analyzed EMPA-KIDNEY in a scientific collaboration with Boehringer Ingelheim and Eli Lilly and Company, announced that EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with Jardiance (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% vs. placebo (HR; 0.72; 95% CI 0.64 to 0.82; P< 0.0001).

In October 2022, Revelation Biosciences Inc. announced positive results in a preclinical model of acute kidney injury (AKI), chronic kidney disease (CKD). Treatment with REVTx-300 significantly reduced renal cortical fibrosis in a dose dependent manner in the medium and high dose groups (21.7% reduction (p < 0.05) and 29.3% (p < 0.05), respectively) and was comparable to a known TGF inhibitor of fibrosis used as a positive control (38.1% reduction (P < 0.05)).

In October 2022, French Biopharma Company, Poxel SA announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD). PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator – and is also a phase 2 ready ADPKD asset, subject to additional financing.

In-depth Commercial Assessment: Chronic Kidney Disease Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Chronic Kidney Disease drugs?
  • How many Chronic Kidney Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Kidney Disease?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Kidney Disease and their status?
  • What are the key designations that have been granted to the emerging and approved drugs?

Key Players

  • Boehringer Ingelheim
  • Eli Lilly and Company
  • Reata Pharmaceuticals
  • Novo Nordisk
  • KBP Biosciences
  • AstraZeneca
  • Allena Pharmaceuticals
  • DiaMedica Therapeutics
  • CinCor Pharma
  • Galapagos NV
  • Sentien Biotechnologies, Inc.
  • Regeneron Pharmaceuticals
  • UnicoCell Biomed
  • OccuRx
  • Pharmicell
  • Lisata Therapeutics
  • Unicycive Therapeutics
  • Senda Biosciences
  • Sarfez Pharmaceuticals
  • Rege Nephro
  • Orgenesis
  • GNI Group
  • Algomedix
  • Maze Therapeutics
  • Chinook Therapeutics
  • Angion Biomedica Corp
  • Arch Biopartners
  • Scohia Pharma
  • Algernon Pharmaceuticals

Key Products

  • Empagliflozin
  • Bardoxolone methyl
  • Ziltivekimab
  • KBP-5074
  • AZD9977
  • ALLN-346
  • BI-685509
  • SCO-792
  • DM199
  • Baxdrostat
  • GLPG2737
  • SBI-101
  • REGN5459
  • FT011
  • Cellgram-CKD
  • CLBS201
  • UNI-494
  • Research Program
  • SZ007
  • Renal progenitor cells
  • F351

Research programme: TRPC6 antagonist

  • APOL1 Programme

Research and discovery programs: severe chronic kidney disease

  • ROCK2 Inhibitor
  • LSALT peptide
  • SCO-116
  • Repirinast
  • Polycystic kidney disease (PKD)

For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


SOURCE Research and Markets

Leave a Reply

Your email address will not be published. Required fields are marked *